US Stock MarketDetailed Quotes

EDIT Editas Medicine

Watchlist

3.270
-0.140-4.11%

Close Oct 1 16:00 ET

3.349
+0.079+2.40%

Post 17:01 ET

269.70MMarket Cap-1403P/E (TTM)

Editas Medicine Stock Forum

wompwomp1337

Sep 6 06:09

$Editas Medicine (EDIT.US)$ seems like Feng Zhang and his team are making leeway with the ultra selfish gene

frankinglily

May 14 03:38

How does the biotech ecosystem support advancements in personalized medicine & genomics?
• Editing Genes | $CRISPR Therapeutics (CRSP.US)$ , $Intellia Therapeutics (NTLA.US)$ , $Beam Therapeutics (BEAM.US)$ , $Verve Therapeutics (VERV.US)$ , $Editas Medicine (EDIT.US)$
• Creating Therapies | $Prime Medicine (PRME.US)$ , $Sana Biotechnology (SANA.US)$
• Building DNA | $Twist Bioscience (TWST.US)$ , $Ginkgo Bioworks (DNA.US)$ , $Pacific Biosciences of California (PACB.US)$ , $Illumina (ILMN.US)$
• Dis...

Jaguar8

May 10 05:01

$Editas Medicine (EDIT.US)$
NEWS
Editas Medicine Preclinical Data Highlights Advancement of in vivo Gene Editing Medicine Technologies at the American Society of Gene and Cell Therapy Annual Meeting
Editas Medicine demonstrated significant scientific advances in in vivo gene editing technologies, including lipid nanoparticle formulations for efficient delivery and guide RNA modifications to enhance editing potency.
The efficacy of AsCas12a nuclease in vivo was demonstrated by Editas Medicine, sho...

Jaguar8

Apr 22 15:32

$Editas Medicine (EDIT.US)$
NEWS
Editas Medicine to Present Pre-clinical Data Demonstrating Progression of in vivo Medicines Pipeline at the American Society of Gene and Cell Therapy Annual Meeting

Moomoo AI

Mar 9 06:33

Despite Editas Medicine's stock price surge, its P/S ratio remains modest due to inferior revenue forecasts. Without revenue improvement, the P/S ratio will continue to limit the share price.

Editas Medicine, Inc. (NASDAQ:EDIT) Surges 28% Yet Its Low P/S Is No Reason For Excitement

Moomoo AI

Mar 2 06:23

Analysts are divided on Editas Medicine's performance, with some optimistic and others pessimistic. The projected increase in losses next year is worrisome, despite the rise in revenue estimates. The company's revenue growth is anticipated to lag behind the broader industry, posing a potential downside.

Editas Medicine, Inc. (NASDAQ:EDIT) Just Reported Yearly Earnings And Analysts Are Lifting Their Estimates

Moomoo AI

Feb 29 04:33

Increased forecast losses for Editas Medicine indicate potential issues, with revenues expected to grow slower than the market. The drastic downgrade to this year's forecasts raises caution towards the company's future performance.

Revenue Downgrade: Here's What Analysts Forecast For Editas Medicine, Inc. (NASDAQ:EDIT)

Moomoo AI

Feb 29 04:31

Editas Medicine's share price bounce is expected after a significant drop, but the underlying business needs to justify a higher price. The weak revenue result is concerning, and the falling share price is likened to 'trying to catch a falling knife'. The recent share price recovery is viewed skeptically.

Editas Medicine (NASDAQ:EDIT) Shareholders Are up 40% This Past Week, but Still in the Red Over the Last Three Years

Moomoo AI

Nov 29, 2023 06:18

Despite recent gains in share price, the company's weak revenue trend and non-profitable status can question future performance. The stock returns also lag behind the market, suggesting potential growth issues.

Strong Week for Editas Medicine (NASDAQ:EDIT) Shareholders Doesn't Alleviate Pain of Three-year Loss

Moomoo AI

Oct 24, 2023 07:24

Citi analyst Samantha Semenkow anticipates FDA experts' positive stance on exa-cel, similar to Zynteglo and Skysona last year. She suggests Beam shares could increase 10%-30% following favorable FDA commentary and sees buoyant future for Editas Medicine on expected AdCom and EDIT-301 data readout.

Editas Upgraded at Citi Ahead of FDA AdCom on Gene Editing Therapy

No comment yet

Analysis

Analyst Rating

No Data

Price Target

No Data

Heat List

Overall

No Data

Concept

Gene Editing

Intraday+0.12%